iBio reports IBIO-610 reduces visceral fat 6.7%, total fat 5.2% in obese NHPs; expands into cardiopulmonary

iBio, Inc.

Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.
Extended half-life of 33.2 days in NHPs; projected human half-life up to 100 days suggesting twice-yearly dosing.
Company announces strategic expansion into cardiopulmonary space, targeting PH-HFpEF with myostatin x Activin A bispecific.
Data consistent with other Activin E pathway approaches; full dataset to be presented at scientific conferences in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.